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Sir,
The association between dietary acrylamide and cancer of the
large bowel, kidney and bladder was assessed in a Swedish case–
control study, with a total of 987 cases and 538 healthy controls,
that originally had been created for evaluating the carcinogenic
effects of heterocyclic amines from diet (Mucci et al, 2003).
Individual dietary acrylamide intakes were crudely estimated from
food frequency questionnaires and reported levels of acrylamide in
frequently consumed food products. No associations were
observed between dietary acrylamide and any cancer risk. The
authors state: ‘The first study of dietary acrylamide in relation to
three major human cancers is reassuring.’ We think that this is too
strong a conclusion.
A basal aspect to consider when interpreting the Swedish
results is the size both of the expected cancer risk enhancement
and of the cancer risk possible to detect. The authors correctly
state, ‘ya true association may be concealed if the level of
exposure in the studied population is low and/or if the range of
variation is limited.’ Unfortunately, the authors provide only
limited information about the estimated daily intake of acrylamide
among cases and controls, which makes it virtually impossible to
get the full picture of absolute levels and interindividual variations
in exposure. The interquartile comparisons given in cannot be
interpreted in terms of absolute levels and variation of exposure.
The only acrylamide dose figures given in the paper concern the
estimated mean daily intakes (27.5mg among the controls and
28.4–29.4mg among the cases), and that less than 2% of the
population was estimated to have a daily intake as high as 1mg
acrylamide per kilogram body weight per day. If we assume an
average body weight of 70kg in the population, those 2% of the
population with a ‘high’ exposure had an estimated excess intake
of about 42.5mg acrylamide per day; this corresponds to an
increase in lifetime cancer mortality of 2.7 per 1000, based on the
risk assessment model of the United States Environmental
Protection Agency (1990). An estimate based on a multiplicative
model (Granath et al, 1999) would arrive at roughly nine extra
cancer deaths per 1000 (To ¨rnqvist et al, 1998). Assuming a
cumulative total cancer mortality of about 18%, and also assuming
that the carcinogenicity of acrylamide is not different with respect
to fatal or nonfatal malignant neoplasms, relative risks for cancers
of approximately 1.015 and 1.05, respectively, could be expected
for those 2% of the Swedish study population with the highest
daily intake of acrylamide as compared to the mean intake. It can
be calculated that from a purely statistical point of view about
470000 (!) cases, with half as many controls, are needed in order to
show a relative risk of 1.05 in a statistically significant way
(Po0.05), and with 80% statistical power, among those 2% with
‘high’ exposure. It can also be calculated that, assuming an
exposure prevalence of 2%, the lowest possible relative risk that
would have 80% chance of being significantly detected in a study
of 987 cases and 538 controls is as high as 2.4; this type of power
calculation assumes that there is no residual confounding or
misclassification bias. However, the Swedish study is likely to
suffer from considerable nondifferential misclassification of
exposure to acrylamide, taking into account both lack of precision
in food frequency questionnaire data and the sparse data on
acrylamide levels in food products that were available for the
intake calculations. Thus, it is not realistic that not even a ‘true’
relative risk as high as 2.4 could have been detected in the Swedish
study.
There is a need to validate the type of exposure assessments for
acrylamide that were used in the Swedish study using biomarkers
for acrylamide exposure, for example, haemoglobin adducts of
acrylamide, which reflect the cumulative dose during the preceding
months (Granath et al, 1992; To ¨rnqvist et al, 2002). It needs to be
assessed first, whether food frequency data can be used for
quantifying dietary intake of acrylamide and second, the variation
in acrylamide intake in the population. More specifically, we need
to know whether there are sufficient subjects with high intake, as
this is a prerequisite for the design of epidemiological studies with
a prospect of evaluating the carcinogenicity to humans of dietary
acrylamide.
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Sir,
We appreciate the comments of Drs Hagmar and
To ¨rnqvist (2003) on our article assessing dietary acrylamide
and cancer risk (Mucci et al, 2003). We take this opportunity
to clarify some issues and to present data from additional
analyses.
We undertook the original investigation in light of claims by the
Swedish National Food Administration that acrylamide in foods
could have global impacts on cancer incidence rates. In spite of the
potential limitations of the study design, our data are reassuring
that acrylamide seems unlikely to be responsible for a major
fraction of these cancers. As stated in our discussion, however,
additional data are needed before a global assessment of any risks
of dietary acrylamide can be undertaken in relation to other cancer
sites and neurological diseases.
The reliance on toxicological risk assessment models employed
by Hagmar and To ¨rnqvist may be questionable. Estimates of
human cancer risk were extrapolated from animal models, given
doses of acrylamide several fold higher than those to which
humans are exposed (International Agency for Research on Cancer
(IARC), 1994). We think that animal data must be generalized to
humans with caution. This sentiment is reflected by IARC (2002)
who considers an agent as definitely carcinogenic to humans when
there is sufficient evidence from studies in humans (i.e.
epidemiological evidence) and only ‘exceptionally’ in other
situations.
The authors present evidence from power analyses on the
substantial sample size needed to detect an effect of acrylamide on
human cancer risk. Notwithstanding the limitations of the risk
assessment models, the authors determined an expected relative
risk of 1.05 for the highest vs lowest dose. An effect estimate of this
size is almost impossible to determine in any observational study.
Indeed, not even a randomised clinical trial would have the power
to detect this effect. The scientific methods to study such a small
effect currently do not exist, and beg the question of how to best
proceed to address the question of acrylamide and cancer. In
addition, we must ask whether a relative risk of this size warranted
the public health alarm that was generated when the findings of
acrylamide in food were first announced.
Additional data
Since our study was published, new data have come available
on acrylamide content in additional food items. In parti-
cular, acrylamide has been detected in coffee. Although the
range of exposure (B8mgkg
1) is lower than other items,
coffee may account for a substantial proportion of total dose
because of the frequency of consumption. We present updated
data from the original case–control study, using a similar
methodology.
Coffee consumption was common in this Swedish population,
with 23.5% of controls consuming four or more cups of coffee per
day. The daily mean (standard error) dietary acrylamide dose (mg)
increased with the addition of coffee data: 34.0 (0.6) for controls,
34.8 (0.6) for colorectal, 36.8 (1.0) for bladder, and 34.5 (1.4) for
kidney cancers. Crisp breads (28%) and coffee intake (20%)
contributed to the largest sources of acrylamide in the diet among
controls (Figure 1). Quartiles of dietary acrylamide dose were
calculated based on the distribution among the controls. Adjusting
for potential confounders, the risk of colorectal (Figure 2A) and
kidney cancers (Figure 2C) decreased with increasing acrylamide
dose. The apparent protective effect of acrylamide parallels the
lower risk associated in this study with crisp breads and for coffee,
a finding consistently observed in the literature (Ekbom, 1999).
The relative risk estimate of acrylamide and bladder cancer was
essentially null (Figure 2B).
Expanding the range of exposure and achieving a more complete
estimate of acrylamide intake, there remains no evidence of an
excess risk of the three studied cancers in relation to acrylamide,
and provides further reassurance that acrylamide in diet does not
appear to be responsible for a major fraction of these three
cancers.
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